Back to Search
Start Over
Response of eosinophilic fasciitis associated with Waldenström macroglobulinemia to rituximab.
- Source :
- Dermatology Online Journal; 2021, Vol. 27 Issue 8, p1-7, 8p
- Publication Year :
- 2021
-
Abstract
- Eosinophilic fasciitis (EF) and generalized morphea (GM) are rare and difficult-to-treat sclerosing skin diseases which may occur in association with hematologic disorders. We present a 66-year-old man with EF and associated Waldenström macroglobulinemia who received combination therapy with rituximab (375mg/m² every other week, gradually extended to every eight weeks), prednisolone (1.25-30mg/d), and methotrexate (7.5-15mg/w). Three months after rituximab initiation, his skin condition improved steadily accompanied by a significant improvement in joint mobility with only mild and transitory flares (observation period: 59 months under treatment with rituximab). To date, there are five case reports on rituximab treatment of EF/GM with an association to hypergammaglobulinemia in three of those cases. Therapy effected significant improvement in four patients. Our case adds to the hitherto limited evidence that rituximab may be a promising therapeutic strategy for EF/GM in association with hypergammaglobulinemia. [ABSTRACT FROM AUTHOR]
- Subjects :
- FASCIITIS
WALDENSTROM'S macroglobulinemia
RITUXIMAB
BLOOD diseases
PREDNISOLONE
Subjects
Details
- Language :
- English
- ISSN :
- 10872108
- Volume :
- 27
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Dermatology Online Journal
- Publication Type :
- Academic Journal
- Accession number :
- 152750112
- Full Text :
- https://doi.org/10.5070/D327854694